Biosimilars are legal and subjected to rigorous testing that ensures that they are as safe and effective as their biological agent counterparts.

Several biosimilars used in oncology include nivolumab, ipilimumab, trastuzumab, bevacizumab and rituximab.

Biosimilars cost much less than branded drugs. This makes them accessible to a broader audience of consumers.

No. Biosimilars are “highly similar” versions of branded drugs while generic medicines are exact copies.

Biosimilars are as safe as the branded drugs they were intended to copy, subjected to rigorous testing against approved referenced products. This ensures that they are “highly similar” and do not have significant variations in clinical effectiveness.